Brought to you by 
Medigene and bluebird partner for TCR immunotherapies; deal expanded
06 Jan 2022
Executive Summary
Medigene AG and bluebird bio Inc. agreed to work together on the discovery and development of T-cell receptor (TCR) immunotherapies against four undisclosed cancer targets.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com